

RESULTS OF EXTRAORDINARY GENERAL MEETING

The Board of Directors (the "Board") of OUE Lippo Healthcare Limited (the "Company") is pleased to announce that at the Extraordinary General Meeting ("EGM") of the Company convened and held by way of electronic means on Friday, 28 January 2022, at 9.00 a.m., the ordinary resolution set out in the Notice of EGM dated 5 January 2022 was duly passed by the Company's shareholders ("Shareholders") by way of poll.

Capitalised terms used herein, unless otherwise defined, have the meanings as defined in the Circular to Shareholders and the Notice of EGM dated 5 January 2022.

The information as required under Rule 704(15) of the Listing Manual of the SGX-ST, Section B: Rules of Catalist is set out below:

(a) Breakdown of all valid votes cast at the EGM:

Resolution and details	Total number of	of For		Against	
	Shares	Number of	As a	Number of	As a
	represented by	Shares	percentage	Shares	percentage
	votes for and		of total		of total
	against the		number of		number of
	resolution		votes for and against		votes for
			the		and against the
			resolution		resolution
			(%)		(%)
Ordinary Resolution	3,985,802,726	3,985,786,726	99.9996	16,000	0.0004
The proposed divestment					
by the Company of					
100.0% of the issued and					
paid-up share capital of					
each of (1) OUELH Japan					
Medical Facilities Pte. Ltd.,					
which owns a 100.0%					
interest in 12 nursing					
homes located in Japan;					
and (2) OUELH Japan					
Medical Assets Pte. Ltd.					
as a major transaction					

(b) Details of parties who are required to abstain from voting on the resolution, including the number of shares held and the individual resolution on which they are required to abstain from voting:

No persons were required to abstain from voting on the resolution at the EGM.

OUE Lippo Healthcare Limited

(c) Name of firm and/or person appointed as scrutineer:

Reliance 3P Advisory Pte. Ltd. was appointed as scrutineer for the EGM.

By Order of the Board

OUE Lippo Healthcare Limited

Mr. Yet Kum Meng Chief Executive Officer and Executive Director 28 January 2022

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.